← All supplements

Pueraria mirifica

Supplement botanical women's health
Aka: white kwao krua, Pueraria candollei
Not medical advice. Check with your doctor or pharmacist before you start, stop or change the timing of anything you take.
How to use
What it’s for
Menopausal vasomotor and urogenital symptoms, small trials
When to take
Daily
Studied for
The phase III trial ran 24 weeks at 50 mg a day
Pros & cons
Pros
  • 50 mg/day matched equine estrogen over 24 weeks, n=60
  • 20–50 mg/day cut bap without endometrial thickening
  • Reviewed as a high-potency phytoestrogen for menopause
Cons
  • Review: long-term safety margin may be fairly narrow
  • Animal data: hyperplasia, irreversible amenorrhea
  • Root powders vary; no standardised therapeutic window
Sources
  1. Pueraria mirifica: a critical review of the ethnobotany, phytochemistry, pharmacology and challenges in standardisation (Front Pharmacol / Europe PMC 2026) — results and conclusion · read 2026-08-27
    what it says
    “Clinical data suggest that its high concentration of potent phytoestrogens effectively mitigates vasomotor symptoms and urogenital syndromes in menopausal women … the translation from traditional use to clinical standardization is hindered by a lack of rigorous pharmacokinetic data”
  2. Europe PMC 2026 P. mirifica review — the phase III trial against conjugated equine estrogen · read 2026-08-27
    what it says
    “A subsequent Phase III randomized controlled trial (n = 60) compared a daily dose of 50 mg of P. mirifica against standard conjugated equine estrogen (CEE) therapy, finding no significant difference in efficacy for reducing MGCS scores over 24 weeks”
  3. Europe PMC 2026 P. mirifica review — bone marker trial · read 2026-08-27
    what it says
    “A randomized, double-blind, placebo-controlled trial (n = 71) indicated that doses of 20–50 mg/day significantly suppressed Bone-specific Alkaline Phosphatase (BAP) levels without stimulating endometrial thickening”
  4. Europe PMC 2026 P. mirifica review — traditional dosage range · read 2026-08-27
    what it says
    “Historical texts specify a dosage range of 30–500 mg/day, recommending a gradual escalation from low to high doses.”
  5. Europe PMC 2026 P. mirifica review — toxicological profile and safety margin · read 2026-08-27
    what it says
    “Current research indicates that its toxicity is clearly dose-dependent and time-cumulative, suggesting that the safety margin for long-term use may be relatively narrow”
  6. Europe PMC 2026 P. mirifica review — animal toxicity findings · read 2026-08-27
    what it says
    “In female rodent models, high-dose exposure (≥100 mg/kg/day) results in significant endocrine-disrupting effects, including endometrial hyperplasia and hydrometra. Critically, in non-human primates, these dosages can induce irreversible amenorrhea”
  7. Europe PMC 2026 P. mirifica review — dual regulatory nature of its estrogenic activity · read 2026-08-27
    what it says
    “while short-term or low-dose application can alleviate postmenopausal vaginal atrophy, chronic high-dose administration carries the risk of stimulating endometrial hyperplasia and potential oncogenesis”
  8. Europe PMC 2026 P. mirifica review — methodological heterogeneity · read 2026-08-27
    what it says
    “The discrepancy in dosages across studies (20 mg vs. 100 mg) and the lack of long-term fracture-reduction data or cardiovascular endpoint studies … prevent a definitive recommendation.”
  9. Europe PMC 2026 P. mirifica review — what is still unknown · read 2026-08-27
    what it says
    “pharmacokinetic and metabolic studies should be expanded to clarify oral bioavailability, metabolite transformation, microbiota-related variability, tissue distribution, and potential herb–drug interactions”
  10. HSA — Guidelines on Prohibited and Restricted Ingredients in Health Supplements and Traditional Medicines, GL-CHPB-1-012 Rev. No. 001 (Oct 2025) · read 2026-08-27
    what it says
    “The objective of this guideline is to highlight the substances of concern when used in HS and TM and is not meant to be an exhaustive list”
Report a correction View as JSON

Updated 2026-08-29. Every line above traces to a numbered source. Kozen-X is not a medical device and does not give medical advice. It lists what published sources have written down — nothing more. A pair not listed is unrecorded, not cleared. Before you start, stop or re-time anything, talk to your doctor or pharmacist.